BMS Reports P-II Study Results of BMS-986278 for the Treatment of Idiopathic Pulmonary Fibrosis
Shots:
- The P-II study evaluating BMS-986278 (30/60 mg, BID) vs PBO in a ratio (1:1:1) in 373 patients with IPF for 26wks.
- The results showed that patients treated with BMS-986278 (60mg) achieved a 62% relative reduction in the rate of change in ppFVC in the while-on-treatment analysis & 54% reduction in the treatment policy analysis while Bayesian analysis showed a ≥95% probability where BMS-986278 was superior in while-on-treatment and treatment policy estimands
- The therapy was well tolerated in both treatment arms, AEs were reported in (76% & 74%) in patients with 30 & 60mg vs 80% in PBO, SAEs (11% & 11% vs 17%), treatment discontinuation rates due to AEs (10% & 7% vs 10%), respectively
Ref: BMS | Image: BMS
Related News:- BMS’ Breyanzi (lisocabtagene maraleucel) Receives EC’s Approval for Relapsed or Refractory Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
